Key Highlights • 2Q 2024 adjusted diluted EPS of $10.12 grew 12% year-over-year 2024 Outlook 2 • Guidance embeds investment in strategic growth initiatives, notably in CarelonRx, as we integrate recent acquisitions and scale key value drivers Strategic Focus Areas 3 • Building a sustainable Medicare Advantage business for the long-term 2 • Operating revenue was impacted by declines in Medicaid membership, partially offset by premium rate increases to cover medical cost trends 1. See "Basis of Presentation" ...